Hussman Strategic Advisors Inc. Purchases New Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Hussman Strategic Advisors Inc. bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 8,400 shares of the biopharmaceutical company's stock, valued at approximately $2,268,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Bessemer Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 69 shares during the period. Crossmark Global Holdings Inc. bought a new position in Alnylam Pharmaceuticals in the 1st quarter valued at about $275,000. GAMMA Investing LLC grew its position in Alnylam Pharmaceuticals by 14.3% in the 1st quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company's stock valued at $166,000 after buying an additional 77 shares in the last quarter. Brighton Jones LLC bought a new position in Alnylam Pharmaceuticals in the 4th quarter valued at about $243,000. Finally, Silvercrest Asset Management Group LLC bought a new position in Alnylam Pharmaceuticals in the 4th quarter valued at about $1,151,000. Institutional investors own 92.97% of the company's stock.

Insider Buying and Selling

In other news, CEO Yvonne Greenstreet sold 31,640 shares of the business's stock in a transaction on Friday, May 30th. The shares were sold at an average price of $304.39, for a total value of $9,630,899.60. Following the sale, the chief executive officer owned 48,948 shares in the company, valued at approximately $14,899,281.72. The trade was a 39.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Stock Performance

ALNY stock traded down $4.16 during midday trading on Friday, hitting $320.53. 581,322 shares of the company traded hands, compared to its average volume of 852,491. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $333.70. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88. The business has a 50 day simple moving average of $306.46 and a 200-day simple moving average of $271.53. The stock has a market capitalization of $41.79 billion, a price-to-earnings ratio of -153.36 and a beta of 0.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The company's revenue was up 20.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.16) EPS. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Ratings Changes

ALNY has been the subject of a number of recent analyst reports. Royal Bank Of Canada increased their target price on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a research report on Friday, March 21st. Canaccord Genuity Group raised their price objective on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a research report on Friday, March 21st. HC Wainwright restated a "buy" rating and set a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. Needham & Company LLC raised their price objective on shares of Alnylam Pharmaceuticals from $320.00 to $377.00 and gave the company a "buy" rating in a research report on Thursday, June 26th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $348.00 and gave the company an "overweight" rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twenty-two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $346.13.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.